This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
TMDX Stock Gains Post Q2 Earnings & Revenue Beat, Margins Up
by Zacks Equity Research
TransMedics stock jumps 10.5% as Q2 EPS beats by 91.7%, revenue rises 37.7%, and operating margin expands 1230 basis points.
Resmed Q4 Earnings & Revenues Beat Estimates, Stock Up, Margins Climb
by Zacks Equity Research
RMD tops Q4 earnings and revenue estimates with double-digit growth, rising margins and strong global device demand.
GKOS Stock Falls Despite Q2 Earnings & Revenues Beat, Guidance Raised
by Zacks Equity Research
Glaukos' second-quarter results showcase a strong uptick in revenues. However, continued operating loss remains a cause of concern.
CONMED Q2 Earnings & Revenues Beat Estimates, 2025 Outlook Raised
by Zacks Equity Research
CNMD reports solid second-quarter results, driven by improving sales across both segments.
Merit Medical Q2 Earnings Beat Estimates, Gross Margin Expands
by Zacks Equity Research
MMSI beats second-quarter 2025 earnings estimates as gross margin expands and strong U.S. and Cardiovascular sales drive revenue growth.
Should You Buy Medpace (MEDP) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Hologic Stock Falls Despite Q3 Earnings and Revenue Beat, Margins Down
by Zacks Equity Research
HOLX posts better-than-expected Q3 results, but margin contraction and regional headwinds pressure investor sentiment.
GE HealthCare Q2 Earnings & Sales Beat Estimates, Net Margin Rises
by Zacks Equity Research
GEHC's second-quarter results reflect strength in the Imaging and Pharmaceutical Diagnostics segments. The bottom line improves with better pricing.
Ecolab Stock Down in Pre-Market Post Q2 Earnings Miss, Margins Expand
by Zacks Equity Research
ECL stock dips in pre-market despite second-quarter 2025 earnings growth and margin expansion, as EPS misses estimates by a penny.
What Makes Medpace (MEDP) a New Strong Buy Stock
by Zacks Equity Research
Medpace (MEDP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Best Momentum Stocks to Buy for July 28th
by Zacks Equity Research
CALX, MEDP and WST made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 28, 2025.
New Strong Buy Stocks for July 28th
by Zacks Equity Research
MEDP, CBFV, CALX, TREE and HAS have been added to the Zacks Rank #1 (Strong Buy) List on July 28, 2025.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Danaher Q2 Earnings Beat Estimates, Life Sciences Sales Up Y/Y
by Zacks Equity Research
DHR tops Q2 estimates with strong sales across segments, lifting its 2025 EPS outlook amid mixed margin trends.
Medpace (MEDP) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Medpace (MEDP) delivered earnings and revenue surprises of +3.33% and +11.48%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
OGN or MEDP: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
OGN vs. MEDP: Which Stock Is the Better Value Option?
Medpace (MEDP) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
Medpace (MEDP) reached $319.16 at the closing of the latest trading day, reflecting a +1.38% change compared to its last close.
Analysts Estimate Icon PLC (ICLR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Medpace (MEDP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Medpace (MEDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Medpace (MEDP) Exceeds Market Returns: Some Facts to Consider
by Zacks Equity Research
In the closing of the recent trading day, Medpace (MEDP) stood at $328.24, denoting a +2.27% move from the preceding trading day.
Brookdale's Occupancy Registers a Rise to 80.5% in June 2025
by Zacks Equity Research
BKD's June occupancy improves 230 bps year over year to 80.5%, driven by stronger move-ins and move-out activity across its senior living communities.
OGN vs. MEDP: Which Stock Is the Better Value Option?
by Zacks Equity Research
OGN vs. MEDP: Which Stock Is the Better Value Option?
Medpace (MEDP) Exceeds Market Returns: Some Facts to Consider
by Zacks Equity Research
Medpace (MEDP) closed the most recent trading day at $326.03, moving +1.55% from the previous trading session.
Medpace (MEDP) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
Medpace (MEDP) closed the most recent trading day at $306.8, moving 1.39% from the previous trading session.
Medpace (MEDP) Dips More Than Broader Market: What You Should Know
by Zacks Equity Research
Medpace (MEDP) closed at $297.92 in the latest trading session, marking a -1.02% move from the prior day.